Chronic Lymphocytic Leukemia

The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.

Jennifer Brown, MD, PhD discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia.

Research results suggest that CAR T-cell therapy can overcome T cell defects caused by chronic lymphocytic leukemia, with remissions possibly lasting more than a decade for patients with significant disease burden when treated with CD4+ CAR T cells

Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.

Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.

The FDA will now make a decision on the approval application for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma in June following an ODAC meeting.

Even with the available agents and knowledge of when to select which option, there is an unmet medical need in the chronic lymphocytic leukemia landscape, according to Jennifer R. Brown, MD, PhD.

Data supporting zanubrutinib for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia will undergo a regular FDA review in consideration for FDA approval.

During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.

During a live virtual event, Javier Pinilla-Ibarz, MD, PhD, discussed treatment options for chronic lymphocytic leukemia including ibrutinib, acalabrutinib, and venetoclax with obinutuzumab.

Jennifer R. Brown, MD, PhD, discusses the patient population of the SEQUOIA trial of zanubrutinib and venetoclax for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.

Major clinical trials are looking to answer substantial questions in the treatment of patients with chronic lymphocytic leukemia, according to Matthew Davids, MD, MMSc.

In an interview with Targeted Oncology, Jennifer Brown, MD, PhD discussed the early analysis of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia and deletion 17p.

During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.